Biotechnology Industry

Found 15,174 articles

• CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology

  10/15/2019

  KSQ Therapeutics to receive non-exclusive access to certain CRISPR IP for its autologous cell therapies, including its existing eTIL™ cell franchise

• Can-Fite Completes Patient Enrollment in Phase II NASH Study of Namodenoson™

  10/15/2019

  Can-Fite BioPharma Ltd. announced it has completed patient enrollment in its Phase II study of Namodenoson in the treatment of NAFLD/NASH.

• Caris Life Sciences Further Bolsters Scientific Advisory Board With Four New Members

  10/15/2019

  Industry thought leaders join a distinguished group of experts to advance Caris' mission to expand the role of precision medicine in cancer care

• Rocket Pharmaceuticals Announces Upcoming Presentations at the European Society of Gene and Cell Therapy Annual Congress

  10/15/2019

  New Long-Term “Process A” Data from the Phase 1/2 EUROFANCOLEN Trial of RP-L102 to be Featured in Oral Session

• Celemics Expedites Target Enrichment NGS Data Insights by Partnering With BlueBee on a Global Genomics Data Solution

  10/15/2019

  Celemics, provider of NGS target enrichment kits and innovative sequencing platforms, announced the release of a comprehensive NGS target enrichment workflow for clinical and translational research applications.

• Bio-Path Holdings Appoints Martina Molsbergen to Board of DirectorsBrings 25 Years of Experience in Business Development and Marketing

  10/15/2019

  Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces the appointment of Martina Molsbergen, Chief Executive Officer of C14 Consulting, to its Board of Directors, effective as of October 11, 2019.

• Anixa Biosciences Appoints Dr. Thomas Schlumpberger as Executive Vice President of Diagnostics to Head Liquid Biopsy Development and Commercialization Efforts

  10/15/2019

  Anixa Biosciences, Inc., a biotechnology company focused on harnessing the body's immune system in the fight against cancer, announced the appointment of Thomas Schlumpberger, Ph.D., as Executive Vice President, Diagnostics.

• Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Squamous Cell Carcinoma

  10/15/2019

  First patient enrolled in registration-directed Phase 2 clinical trial of RP1 in combination with Regeneron and Sanofi’s Libtayo® in CSCC

• Novavax Initiates Pivotal Phase 3 Clinical Trial of NanoFlu Influenza Vaccine in Older Adults

  10/15/2019

  Novavax, Inc. announced the initiation of a pivotal Phase 3 clinical trial for NanoFlu™, its recombinant quadrivalent seasonal influenza vaccine candidate, in adults aged 65 and over.

• Neurana Pharmaceuticals to Participate in Solebury Trout Private Company Showcase

  10/15/2019

  Neurana Pharmaceuticals, a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced that Craig Thompson, president and chief executive officer, will present at the Solebury Trout Private Company Showcase, on Friday, October 18 at 10:20 a.m. Eastern Time at Davis Polk & Wardwell, LLP in New York.

• Arcadia Biosciences Advances Hemp Operations with Archipelago Ventures

  10/15/2019

  The company is scaling its Hawaiian hemp cultivation footprint, introducing a new autoflowering varietal and initiating oil extraction operations on the islands

• 

  The Challenge of Cultured Meat

  10/14/2019

  Aleph Farms announced last week they 3D printed a small piece of muscle tissue on the International Space Station. The success of this miniature steak highlights the key advantage of cultivated meat: you can make it anywhere.
• 

  Employees’ Perception vs. Employers’ Reality!  New Research Shows the Top 3 Areas of Opportunity

  10/14/2019

  What makes an organization a desirable employer?  Do they need to be a large company with a recognizable name?  Should the organization pay their employees more than others?
• 

  Targeting Life Sciences Employers Based on Their Needs

  10/14/2019

  A successful targeted job search is not a scattershot approach like my spammer’s. It is narrowly focused on a finite list of employers that you’ve generated and qualified.
• 

  Clinical Catch-Up: October 7-11

  10/14/2019

  It was a busy week for clinical trial announcements. Here’s a look.

• Exicure to Present Clinical Results from XCUR17 at the 15th Annual Meeting of the Oligonucleotide Therapeutics Society

  10/14/2019

  Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced that its CEO, David Giljohann, PhD, will present clinical data from the company’s Phase 1 study of its drug candidate XCUR17 in psoriasis.

• Forbius Completes Enrollment into Phase 1a Solid Tumor Trial of AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor; Closes Series C Financing

  10/14/2019

  AVID200 is a first-in-class, selective inhibitor of TGF-beta 1 & 3, the main pathogenic TGF-beta isoforms; AVID200 spares TGF-beta 2 for optimal safety

• Revance Appoints Mark J. Foley as President and CEO, Replacing Dan Browne

  10/14/2019

  Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced the appointment of Mark Foley as President and CEO, replacing Dan Browne, who has stepped down due to a misjudgment in handling an employee matter.

• I-Mab Biopharma and MorphoSys Announce IND Clearance to Initiate Clinical Trials of TJ202/MOR202 for the Treatment of Multiple Myeloma in Mainland China

  10/14/2019

  I-Mab Biopharma and MorphoSys AG announced that I-Mab has received Investigational New Drug clearances from the National Medical Products Administration of China to expand the ongoing phase II and III clinical trials of TJ202/MOR202, MorphoSys's human monoclonal anti-CD38 antibody for the treatment of multiple myeloma, also to mainland China.

• Paragon Genomics Introduces New CleanPlex® Hereditary Cancer Panel V2 At American Society For Human Genetics 2019 Annual Meeting

  10/14/2019

  Improved Version of Hereditary Cancer Panel Facilitates Same-Day Risk Assessment of Multiple Hereditary Cancers with Reduced Sample Input, Greater Ease of Use and 3-Hour Workflow